Pyxis Oncology, Inc.
PYXS
$1.70
$0.010.59%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -17.53% | -8.59% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.15% | 25.75% | |||
| Operating Income | -34.80% | 22.72% | |||
| Income Before Tax | -36.87% | 22.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -28.53% | 17.71% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -28.53% | 17.71% | |||
| EBIT | -34.80% | 22.72% | |||
| EBITDA | -53.69% | 33.91% | |||
| EPS Basic | -27.64% | 18.31% | |||
| Normalized Basic EPS | -35.94% | 23.29% | |||
| EPS Diluted | -28.79% | 18.31% | |||
| Normalized Diluted EPS | -35.94% | 23.29% | |||
| Average Basic Shares Outstanding | 0.70% | 0.76% | |||
| Average Diluted Shares Outstanding | 0.70% | 0.76% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||